Clinical and economic efficiency of treatment of patients with tuberculosis combined with HIV infection in the Republic Karelia

The article presents the results of an analysis of the direct costs of treating tuberculosis patients with various types of drug resistance combined with HIV infection in the Republic of Karelia, as well as calculations of the clinical and economic effectiveness of treatment of combined infection. It was found that the cost of treating one patient with tuberculosis combined with HIV infection varied depending on the type of drug resistance: from 316,828 rubles with preserved drug sensitivity to 1,210,470 rubles with very wide drug resistance. A significant part of the costs fell on inpatient treatment, which cost from 234,277 to 273,619 rubles, while the average duration of hospitalization was 2-3 times higher than the average European standards. Indicators of clinical and economic efficiency, reflecting the cost of therapy, taking into account the effectiveness of treatment of patients with tuberculosis combined with HIV infection, increase three times, compared with direct costs, for multidrug-resistant and extremely drug-resistant tuberculosis (1,916,584 rubles and 3,631,411 rubles) due to the low effectiveness of treatment.